We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Panel Votes Down Intellipharmaceutics’ Abuse-Deterrent Opioid
FDA Advisory Panel Votes Down Intellipharmaceutics’ Abuse-Deterrent Opioid
A joint FDA advisory committee voted against recommending approval of Intellipharmaceutics’ extended-release opioid painkiller Rexista, as well as against the claim that it deters abuse.